95 results on '"S. Giard"'
Search Results
2. Association between oral and fecal microbiome dysbiosis and treatment complications in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
- Author
-
M. Faraci, C. Bonaretti, G. Dell’Orso, F. Pierri, S. Giardino, F. Angiero, S. Blasi, G. Farronato, E. Di Marco, A. Trevisiol, E. Olcese, L. Rufino, M. Squillario, and R. Biassoni
- Subjects
Oral microbiome ,Gut microbiome ,Hematopoietic stem cell transplant (HSCT) ,Mucositis ,Graft versus host disease (GvHD) ,Medicine ,Science - Abstract
Abstract The oral and gastrointestinal mucosae represent the main targets of the toxic effect of chemo and/or radiotherapy administered during the conditioning regimen before hematopoietic stem cell transplant (HSCT). These harmful consequences and the immunological complications that may occur after the transplant (such as Graft versus Host Disease, GvHD) are responsible for the clinical symptoms associated with mucositis during the aplasia phase, like pain, nausea, vomiting, and diarrhea. These toxicities could play a critical role in the oral and gastrointestinal microbiomes during the post-transplant phase, and the degree of microbial dysbiosis and dysregulation among different bacterial species could also be crucial in intestinal mucosa homeostasis, altering the host’s innate and adaptive immune responses and favoring abnormal immune responses responsible for the occurrence of GvHD. This prospective pediatric study aims to analyze longitudinally oral and gut microbiomes in 17 pediatric patients who received allogeneic HSCT for malignant and non-malignant diseases. The oral mucositis was mainly associated with an increased relative abundance of Fusobacteria, and Prevotella species, while Streptococcus descendants showed a negative correlation. The fecal microbiome of subjects affected by cutaneous acute GvHD (aGvHD) correlated with Proteobacteria. Oral mucosal microbiota undergoes changes after HSCT, Fusobacteria, and Prevotella represent bacterial species associated with mucositis and they could be the target for future therapeutic approaches, while fecal microbiome in patients with acute GvHD (aGvHD) revealed an increase of different class of Proteobacteria (Alphaproteobacteria and Deltaproteobacteria) and a negative correlation with the class of Gammaproteobacteria.
- Published
- 2024
- Full Text
- View/download PDF
3. Do no harm: The know-do gap and quality of care for childhood diarrhea and pneumonia in Bihar, India
- Author
-
M. Mohanan, M. Vera-Hernández, V. Das, S. Giardili, J. Goldhaber-Fiebert, T. Rabin, S. Raj, J. Schwartz, and A. Seth
- Subjects
Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Published
- 2014
- Full Text
- View/download PDF
4. Good response with zinc acetate monotherapy in an adolescent affected by severe Wilson disease
- Author
-
M.G. Marazzi, S. Giardino, C. Dufour, M. Serafino, D. Sperlì, and R. Giacchino
- Subjects
Haemolytic anaemia ,Wilson disease ,zinc acetate ,Pediatrics ,RJ1-570 ,Surgery ,RD1-811 - Abstract
We describe a 17-year-old girl with haemolytic anaemia as presentation of Wilson disease. The diagnosis was based on the findings of < 20 mg/dl ceruloplasmin serum level, Kayser-Fleischer ring and Coombs-negative haemolytic anaemia. Genetic testing revealed the presence of the H1069Q heterozygous mutation. The patient was treated with Zinc acetate monotherapy, with good response, maintened after 22 months. This case emphasizes the importance of recognizing atypical clinical presentation of Wilson disease, which must always be considered in patients with Coombs-negative haemolytic anaemia. The good clinical response to treatment with zinc acetate monotherapy in our case might lend to consider the use of zinc monotherapy as initial therapy also in symptomatic patients with Wilson disease under close clinical observation. Clinical trials are needed to provide evidence for use of zinc monotherapy as first-line therapy in symptomatic patients with Wilson disease.
- Published
- 2012
- Full Text
- View/download PDF
5. North Atlantic right whale shift to the Gulf of St. Lawrence in 2015, revealed by long-term passive acoustics
- Author
-
Y Simard, N Roy, S Giard, and F Aulanier
- Subjects
Zoology ,QL1-991 ,Botany ,QK1-989 - Abstract
This paper contributes to documenting a change in the distribution of North Atlantic right whales Eubalaena glacialis (NARWs) that occurred in the 2010s, when the whales largely abandoned their traditional summering grounds in the Gulf of Maine/Bay of Fundy/Scotian shelf. Data from a year-round passive acoustic monitoring (PAM) network in the Gulf of St. Lawrence were exploited to build the time series of NARW incursions into this inland sea of the Northwest Atlantic, from June 2010 to November 2018. NARWs visited the southern Gulf of St. Lawrence every year from June to January, until ice freeze-up. The earliest detections were made at the end of April and the latest in mid-January. Call occurrence peaked between August and the end of October. NARW contact calls were not detected at the most upstream station at Les Escoumins, in the Lower St. Lawrence estuary, or at the northeastern connection of Belle Isle Strait with the Atlantic, which was monitored from November 2010 to November 2011. The mean daily occurrence of NARWs in the feeding grounds off Gaspé quadrupled after 2015 compared to 2011-2014. Long-term continuous PAM data provided invaluable information to document this marine mammal distribution shift.
- Published
- 2019
- Full Text
- View/download PDF
6. Standards, Options et Recommandations 2001 pour la radiothérapie des patientes atteintes d'un cancer du sein infiltrant non métastatique, mise à jour
- Author
-
A., Fourquet, B., Cutuli, E., Luporsi, L., Mauriac, J.R., Garbay, S., Giard, F., Spyratos, B., Sigal-Zafrani, J.M., Dilhuydy, V., Acharian, C., Balu-Maestro, M.P., Blanc-Vincent, C., Cohen-Solal, B., De Lafontan, M.H., Dlhuydy, B., Duquesne, R., Gilles, A., Lesur, N., Shen, and L., Cany
- Published
- 2002
- Full Text
- View/download PDF
7. Mesoscale habitat use by St. Lawrence estuary beluga over the annual cycle from an acoustic recording network.
- Author
-
Simard Y, Giard S, Roy N, Aulanier F, and Lesage V
- Abstract
The spatial-temporal distribution pattern of St. Lawrence Estuary (SLE) beluga is examined with a passive acoustic monitoring network of 13 stations from June 2018 to October 2021. A beluga calling index, correlated with beluga density, is used as a proxy for habitat use by the population at weekly, monthly, and yearly scales. The seasonal pattern along SLE upstream-downstream axis was repeated annually. In summer, beluga habitat was confined to a 150 km segment of the SLE, with higher occurrences in its ∼20 km central portion, including the head of the Laurentian Channel and Saguenay Fjord mouth. During fall, the distribution gradually shifted to the downstream portion of the SLE and into the Northwestern Gulf, leaving low to no occurrences upstream in winter, until the spring return, characterized by the highest upstream occurrences. Occurrences off Ste. Marguerite Bay, 25 km upstream in Saguenay Fjord, were essentially from June to October. This multi-year continuous habitat use pattern provides a baseline for year-round SLE beluga distribution dynamics for assessing and mitigating anthropogenic threats to this endangered population, such as shipping noise. It also provides insights for optimizing the assessments of population size from aerial line transect surveys., (© 2023 Acoustical Society of America All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).)
- Published
- 2023
- Full Text
- View/download PDF
8. Performance of a deep neural network at detecting North Atlantic right whale upcalls.
- Author
-
Kirsebom OS, Frazao F, Simard Y, Roy N, Matwin S, and Giard S
- Subjects
- Algorithms, Animals, Atlantic Ocean, Discriminant Analysis, Neural Networks, Computer, Acoustics, Whales
- Abstract
Passive acoustics provides a powerful tool for monitoring the endangered North Atlantic right whale (Eubalaena glacialis), but robust detection algorithms are needed to handle diverse and variable acoustic conditions and differences in recording techniques and equipment. This paper investigates the potential of deep neural networks (DNNs) for addressing this need. ResNet, an architecture commonly used for image recognition, was trained to recognize the time-frequency representation of the characteristic North Atlantic right whale upcall. The network was trained on several thousand examples recorded at various locations in the Gulf of St. Lawrence in 2018 and 2019, using different equipment and deployment techniques. Used as a detection algorithm on fifty 30-min recordings from the years 2015-2017 containing over one thousand upcalls, the network achieved recalls up to 80% while maintaining a precision of 90%. Importantly, the performance of the network improved as more variance was introduced into the training dataset, whereas the opposite trend was observed using a conventional linear discriminant analysis approach. This study demonstrates that DNNs can be trained to identify North Atlantic right whale upcalls under diverse and variable conditions with a performance that compares favorably to that of existing algorithms.
- Published
- 2020
- Full Text
- View/download PDF
9. Decadal passive acoustics time series of St. Lawrence estuary beluga.
- Author
-
Giard S, Simard Y, and Roy N
- Abstract
Passive acoustics is used to monitor the threatened St. Lawrence estuary beluga between 2007 and 2017 from a site downstream of the beluga summer habitat. Acoustic metrics of presence and occurrence based on beluga acoustic band activity (BABA) are extracted by a dedicated algorithm adapted for the shipping noise from the St. Lawrence Seaway. A formal optimization process is used to set the algorithm parameters. Results evidence a year-round occurrence of belugas in the region, seasonal and diel patterns, and significant inter-annual variations. This study shows how passive acoustics methodology can be applied to monitor a loquacious species over multi-year periods in a shipping-noise-dominated environment, in order to understand its use of the habitat over the continuum of ecologically significant time scales.
- Published
- 2020
- Full Text
- View/download PDF
10. Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.
- Author
-
Houvenaeghel G, Lambaudie E, Classe JM, Mazouni C, Giard S, Cohen M, Faure C, Charitansky H, Rouzier R, Daraï E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, Chauvet MP, and Boher JM
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms therapy, Female, Humans, Lymph Nodes metabolism, Lymphatic Metastasis, Middle Aged, Neoplasm Grading, Nomograms, Retrospective Studies, Sentinel Lymph Node Biopsy, Tumor Burden, Breast Neoplasms diagnosis, Lymph Nodes pathology, Models, Biological, Phenotype
- Abstract
Background: A strong correlation between breast cancer (BC) molecular subtypes and axillary status has been shown. It would be useful to predict the probability of lymph node (LN) positivity., Objective: To develop the performance of multivariable models to predict LN metastases, including nomograms derived from logistic regression with clinical, pathologic variables provided by tumor surgical results or only by biopsy., Methods: A retrospective cohort was randomly divided into two separate patient sets: a training set and a validation set. In the training set, we used multivariable logistic regression techniques to build different predictive nomograms for the risk of developing LN metastases. The discrimination ability and calibration accuracy of the resulting nomograms were evaluated on the training and validation set., Results: Consecutive sample of 12,572 early BC patients with sentinel node biopsies and no neoadjuvant therapy. In our predictive macro metastases LN model, the areas under curve (AUC) values were 0.780 and 0.717 respectively for pathologic and pre-operative model, with a good calibration, and results with validation data set were similar: AUC respectively of 0.796 and 0.725. Among the list of candidate's regression variables, on the training set we identified age, tumor size, LVI, and molecular subtype as statistically significant factors for predicting the risk of LN metastases., Conclusions: Several nomograms were reported to predict risk of SLN involvement and NSN involvement. We propose a new calculation model to assess this risk of positive LN with similar performance which could be useful to choose management strategies, to avoid axillary LN staging or to propose ALND for patients with high level probability of major axillary LN involvement but also to propose immediate breast reconstruction when post mastectomy radiotherapy is not required for patients without LN macro metastasis.
- Published
- 2019
- Full Text
- View/download PDF
11. Sentinel lymph node biopsy validation for large tumors.
- Author
-
Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, and Lambaudie E
- Subjects
- Adult, Aged, Axilla, Cohort Studies, False Negative Reactions, Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Middle Aged, Retrospective Studies, Breast Neoplasms pathology, Sentinel Lymph Node Biopsy
- Abstract
Background: Sentinel lymph node biopsy (SLNB) remains under discussion for large size tumors. The aim of this work has been to study the false negative rate (FNR) of SLNB for large tumors and predictive factors of false negative (FN)., Materials and Methods: A study of a multicentric cohort, involved patients presenting N0 breast cancer with a SLNB eventually completed by complementary axillary lymph node dissection (cALND). The main criteria were the FNR and the predictive factors of FN., Results: 12.415 patients were included: 748 with tumors ≥30 mm, 1101 with tumors >20 and < 30 mm and 10.566 with tumors ≤20 mm, with a cALND respectively for 501 patients (67%), 523 (62.1%) and 2775 (26.3%). The FNR were respectively: 3.05% (IC95%: 1.3-4.8) for tumors ≥30 mm*, 3.5% (1.8-5.2) for tumors >20 and < 30 mm*, 1.8% (1-2.4) for tumors ≤20 mm (p < 0.05) (*Not significant). At multivariate analysis, SN number harvested ≤2 (OR:2.0, p = 0.023) and tumor size >20 and < 30 mm (OR:2.07, p = 0.017) were significant predictive factors of FN, without significant value for tumor size ≥30 mm (OR:1.83, p = 0.073)., Conclusion: The FNR of SLNB was not higher amongst large size tumors compared to tumors of a smaller size. These results support the validation of SNLB for tumors up to 50 mm., (Copyright © 2017. Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
12. Nipple sparing mastectomy for breast cancer is associated with high patient satisfaction and safe oncological outcomes.
- Author
-
Mesdag V, Régis C, Tresch E, Chauvet MP, Boulanger L, Collinet P, and Giard S
- Subjects
- Adult, Aged, Body Image, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating surgery, Disease-Free Survival, Esthetics, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Quality of Life, Retrospective Studies, Breast Neoplasms surgery, Mastectomy methods, Patient Satisfaction
- Abstract
Background: The preservation of the nipple areolar complex (NAC) for cancer treatment is still a matter of debate because of suspected increase of local recurrence and surgery-specific complications. The aim of the study was to investigate both the relapse risk associated with nipple sparing mastectomy (NSM) for breast cancer and women's satisfaction with preservation of the NAC., Methods: We included retrospectively all patients who had skin-sparing mastectomy (SSM) or NSM from 2007 to 2012 for breast cancer or ductal carcinoma in situ (DCIS). We compared NSM and SSM group for oncological and surgical outcomes. Patients' satisfaction and quality of life has been evaluated by a specifically designed questionnaire., Results: We included 63NSM (41.5%) and 89SM (58.5%). Eighty-nine (58.6%) patients had DCIS, and the other had small invasive disease. Median follow-up was 42 (IQR: 18-58) months. Local recurrence rate was 1.7% (n=1) in the NSM group and 0% in the SSM group without recurrence in the preserved nipple. After NSM, one patient had complete NAC necrosis, and three patients suffered partial necrosis. Satisfaction with the NAC was higher in the NSM group compared to the SSM group with delayed reconstruction of the nipple (75% vs. 59%, P=0.14). Patients with NSM required less psychological support before (P=0.028) and immediately after surgery (P=0.14) than patients in the SSM group., Conclusion: NSM can successfully and safely be performed for pre-invasive and small invasive breast cancer. Besides esthetic aspects, preserving the nipple may ease the acceptance of these radical form of surgery., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
13. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
- Author
-
de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, and Houvenaeghel G
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast secondary, Chemotherapy, Adjuvant, Chi-Square Distribution, Disease-Free Survival, Female, France, Humans, Kaplan-Meier Estimate, Logistic Models, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Patient Selection, Propensity Score, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology, Tumor Burden, Antineoplastic Agents therapeutic use, Carcinoma, Ductal, Breast therapy, Mastectomy adverse effects, Triple Negative Breast Neoplasms therapy
- Abstract
Background: Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains controversial and evidence that adjuvant chemotherapy (CT) is effective in these small tumours remains limited., Patients and Methods: Our objective was to investigate the impact of CT on survival in pT1abN0M0 TNBC. Patients were retrospectively identified from a cohort of 22,475 patients who underwent primary surgery in 15 French centres between 1987 and 2013. As rare pathological types may display very particular prognoses in these tumours, we retained only the invasive ductal carcinomas of no special type according to the last World Health Organisation (WHO) classification which is the most common TNBC histological type. End-points were disease-free survival (DFS) and metastasis-free survival (MFS). A propensity score for receiving CT was estimated using a logistic regression including age, tumour size, Scarff Bloom and Richardson (SBR) grade and lymphovascular invasion., Results: Of a total of 284 patients with pT1abN0M0 ductal TNBC, 144 (51%) received CT and 140 (49%) did not. Patients receiving CT had more adverse prognostic features, such as tumour size, high grade, young age, and lymphovascular invasion. CT was not associated with a significant benefit for DFS (Hazard ratio, HR = 0.77 [0.40-1.46]; p = 0.419, log-rank test) or MFS (HR = 1.00 [0.46-2.19]; p = 0.997), with 5-year DFS and MFS in the group with CT versus without of 90% [81-94%] versus 84% [74-90%], and 90% [81-95%] versus 90% [83%-95%], respectively. Results were consistent in all supportive analyses including multivariate Cox model and the use of the propensity score for adjustment and as a matching factor for case-control analyses., Conclusions: This study did not identify a significant DFS or MFS advantage for CT in subcentimetric, node-negative ductal TNBC. Although current consensus guidelines recommend consideration of CT in all TNBC larger than 5 mm, clinicians should carefully discuss benefit/risk ratio with patients, given the unproven benefits., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
14. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
- Author
-
Houvenaeghel G, Lambaudie E, Cohen M, Classe JM, Reyal F, Garbay JR, Giard S, Chopin N, Martinez A, Rouzier R, Daraï E, Colombo PE, Coutant C, Gimbergues P, Azuar P, Villet R, Tunon de Lara C, Barranger E, Sabiani L, and Goncalves A
- Subjects
- Adult, Aged, Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Agents, Immunological therapeutic use, Axilla, Breast Neoplasms metabolism, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Lymphatic Metastasis, Mastectomy, Middle Aged, Neoplasm Staging, Radiotherapy, Adjuvant, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Retrospective Studies, Sentinel Lymph Node Biopsy, Survival Rate, Trastuzumab therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms pathology, Breast Neoplasms therapy, Lymph Node Excision
- Abstract
Introduction: The aim of this study was to examine changes in therapeutic practices for early breast cancer T0-2 N0 managed by upfront surgery and SLNB., Population: Between 1999 and 2012, 15.508 patients were treated. Four periods were determined: 1999-2003, 2004-2006, 2007-2009 and > 2009. Five tumor subtypes were defined according to hormonal receptors (HR) and Her2: Luminal A (HR + Her2- Grade 1-2), Her2 (Her2+ HR-), Triple-negative (HR- Her2-), Luminal B Her2- (HR + Her2- Grade 3), Luminal B Her2+ (HR + HER2+)., Methods: Rates of axillary lymph node dissection (ALND), adjuvant chemotherapy ± trastuzumab, endocrine treatment, mastectomy and post mastectomy radiotherapy (PMRT) were analyzed according to treatment periods with univariate and multivariate analysis. Overall and disease-free survivals were analyzed according to treatment periods adjusted for HR and then for tumor subtypes., Results: Rates of ALND, adjuvant chemotherapy and endocrine treatment varied significantly according to treatment periods, for HR positive and negative tumors. ALND rate decreased for all tumor subtypes with a decrease of adjuvant chemotherapy rate for Luminal A tumors and an increase for Luminal B Her2+ and Her2-tumors. Endocrine treatment rate decreased for Luminal A and increased for Luminal B Her2+ tumors. In multivariate analysis, these modifications with time remained significant. Mastectomy and PMRT rates increased. In multivariate analysis, overall and disease-free survivals increased during successive periods., Conclusion: A global therapeutic de-escalation in ALND and adjuvant systemic treatment, combined with an actual escalation in some specific subsets was demonstrated, but without negative impact on survival., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
15. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
- Author
-
de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, and Houvenaeghel G
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms mortality, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Grading, Neoplasm Staging, Trastuzumab administration & dosage, Treatment Outcome, Tumor Burden, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Receptor, ErbB-2 metabolism
- Abstract
Purpose: Benefit of adjuvant trastuzumab-based chemotherapy for node-positive and/or >1 cm human epidermal growth factor receptor 2-positive (HER2+) breast carcinomas has been clearly demonstrated in randomized clinical trials. Yet, evidence that adjuvant chemotherapy with or without trastuzumab is effective in pT1abN0 HER2+ tumors is still limited. The primary objective of this study was to investigate the impact of adjuvant chemotherapy ± trastuzumab on outcome in this subpopulation., Patients and Methods: A total of 356 cases of pT1abN0M0 HER2 + breast cancers were retrospectively identified from a large cohort of 22,334 patients, including 1248 HER2+ patients who underwent primary surgery at 17 French centers, between December 1994 and January 2014. The primary end point was disease-free survival (DFS). A multivariate Cox model was built, including adjuvant chemotherapy, tumor size, hormone receptor status, and Scarff Bloom Richardson (SBR) grade., Results: A total of 138 cases (39%) were treated with trastuzumab-based chemotherapy, 29 (8%) with chemotherapy alone, and 189 (53%) received neither trastuzumab nor chemotherapy. Adjuvant chemotherapy ± trastuzumab was associated with a significant DFS benefit (3-year 99 vs. 90%, and 5-year 96 vs. 84%, Hazard ratio, HR 0.26 [0.10-0.67]; p = 0.003, logrank test) which was maintained in multivariate analysis (HR 0.19 [0.07-0.52]; p = 0.001). Metastasis-free survival was also increased (HR 0.25 [0.07-0.86]; p = 0.018, logrank test) at 3-year (99 vs. 95%) and 5-year (98 vs. 89%) censoring. Exploratory subgroup analysis found DFS benefit to be significant in hormone receptor-negative, hormone receptor-positive, and pT1b tumors, but not in pT1a tumors., Conclusions: Adjuvant chemotherapy ± trastuzumab is associated with a significantly reduced risk of recurrence in subcentimeter node-negative HER2+ breast cancers. Most of the benefit may be driven by pT1b tumors.
- Published
- 2017
- Full Text
- View/download PDF
16. Upper outer boundaries of the axillary dissection. Result of the SENTIBRAS protocol: Multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection.
- Author
-
Nos C, Clough KB, Bonnier P, Lasry S, Le Bouedec G, Flipo B, Classe JM, Missana MC, Doridot V, Giard S, Charitansky H, Charles-Nelson A, Bats AS, and Ngo C
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Axilla surgery, Breast Cancer Lymphedema epidemiology, Breast Neoplasms pathology, Clinical Protocols, Feasibility Studies, Female, Humans, Lymph Nodes pathology, Middle Aged, Neoadjuvant Therapy, Postoperative Complications epidemiology, Sentinel Lymph Node Biopsy, Breast Neoplasms surgery, Lymph Node Excision methods, Sentinel Lymph Node pathology
- Abstract
Background: Two thirds of node-positive breast cancer patients have limited pN1 disease and could benefit from a less extensive axillary lymph node dissection (ALND)., Methods: 172 breast cancers patients requiring an ALND were prospectively enrolled in the Sentibras Protocol of Axillary Reverse Mapping (ARM). Radioisotope was injected in the ipsilateral hand the day before surgery. ALND was standard. Removed lymph nodes were classified into non radioactive nodes and radioactive nodes (ARM nodes). Among ARM nodes, nodes located in the upper outer part of the axilla, above the second intercostal brachial nerve and lateral to the lateral thoracic vein were identified as "zone D ARM nodes". The main objective was: feasibility of identification of the zone D ARM nodes. Secondary objectives were: metastatic involvement and lymphedema rate., Results: 100% of patients had ARM nodes identified. The "zone D ARM nodes" were identified in 92% of cases. The rate of metastatic nodes was 60% in the all cohort, 31% in ARM nodes and 9% in zone D ARM nodes. Among those, metastatic rate was 6% in patients undergoing ALND for a positive sentinel node biopsy, 6% in case of primary ALND versus 14% after neo-adjuvant chemotherapy (p < 0.05). After 34 months of median follow up, 27% of interviewed patients had a lymphedema., Conclusion: The ARM technique reliably identifies the "zone D ARM nodes". These nodes can also easily be identified using knowledge of axillary anatomy. In selected patients, a selective ALND sparing the zone D ARM nodes could be performed., (Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
17. Exclusive intraoperative radiotherapy for invasive breast cancer in elderly patients (>70 years): proportion of eligible patients and local recurrence-free survival.
- Author
-
Lambaudie E, Houvenaeghel G, Ziouèche A, Knight S, Dravet F, Garbay JR, Giard S, Charitansky H, Cohen M, Faure C, Hudry D, Azuar P, Villet R, Gimbergues P, de Lara CT, Tallet A, Bannier M, Minsat M, and Resbeut M
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Ductal, Breast mortality, Disease-Free Survival, Female, Humans, Intraoperative Care, Middle Aged, Patient Selection, Retrospective Studies, Treatment Outcome, Young Adult, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Mastectomy, Radiotherapy, Adjuvant
- Abstract
Background: To estimate the proportion of elderly patients (>70 years) with breast cancer eligible for an Exclusive IntraOperative RadioTherapy (E-IORT) and to evaluate their local recurrence-free survival rate., Methods: This retrospective study examining two cohorts focuses on patients over 70 years old: a multi-centric cohort of 1411 elderly patients and a mono-centric cohort of 592 elderly patients. All patients underwent conservative surgery followed by external radiotherapy for T0-T3 N0-N1 invasive breast cancer, between 1980 and 2008., Results: Within each cohort two groups were identified according to the inclusion criteria of the RIOP trial (R group) and TARGIT E study (T group). Each group was divided into two sub-groups, patients eligible (E) or non-eligible (nE) for IORT. The population of patients that were eligible in the TARGIT E study but not in the RIOP trial were also studied in both cohorts. The proportion of patients eligible for IORT was calculated, according to the eligibility criteria of each study. A comparison of the 5-year local or locoregional recurrence-free survival rate between eligible vs non-eligible patients was made. In both cohorts, the proportion of patients eligible according to the RIOP trial's eligibility criteria was 35.4 and 19.3%, and according to the TARGIT E study criteria was 60.9 and 45.3%. The 5-year locoregional recurrence-free survival rate was not significantly different between RE and RnE groups, TE and TnE groups. In both cohorts RE and (TE-RE) groups were not significantly different., Conclusions: Our results encourage further necessary studies to define and to extend the eligibility criteria for per operative exclusive radiotherapy.
- Published
- 2016
- Full Text
- View/download PDF
18. Erratum: Analysis and modeling of 255 ship source levels from an acoustic observatory along St. Lawrence Seaway [J. Acoust. Soc. Am. 140(3), 2002-2018 (2016)].
- Author
-
Simard Y, Roy N, Gervaise C, and Giard S
- Published
- 2016
- Full Text
- View/download PDF
19. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
- Author
-
Houvenaeghel G, Boher JM, Reyal F, Cohen M, Garbay JR, Classe JM, Rouzier R, Giard S, Faure C, Charitansky H, Tunon de Lara C, Daraï E, Hudry D, Azuar P, Gimbergues P, Villet R, Sfumato P, and Lambaudie E
- Subjects
- Adult, Aged, Aged, 80 and over, Axilla, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular pathology, Cohort Studies, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Proportional Hazards Models, Retrospective Studies, Survival Rate, Young Adult, Breast Neoplasms surgery, Carcinoma, Ductal, Breast surgery, Carcinoma, Lobular surgery, Lymph Node Excision methods, Neoplasm Micrometastasis pathology, Neoplasm Recurrence, Local epidemiology, Sentinel Lymph Node pathology
- Abstract
Background: Omission of completion axillary lymph node dissection (ALND) is a standard practice in patients with breast cancer (BC) and negative sentinel nodes (SNs) but has shown insufficient evidence to be recommended in those with SN invasion., Methods: A retrospective analysis of a cohort of patients with BC and micrometastases (Mic) or isolated tumour cells (ITCs) in SN. Factors associated with ALND were identified, and patients with ALND were matched to patients without ALND. Overall survival (OS) and recurrence-free survival (RFS) were estimated in the overall population, in Mic and in ITC cohorts., Findings: Among 2009 patients analysed, 1390 and 619 had Mic and ITC in SN, respectively. Factors significantly associated with ALND were SN status, histological type, age, number of SN harvested and absence of adjuvant chemotherapy. After a median follow-up of 60.4 months, ALND omission was independently associated with reduced OS (hazard ratio [HR] 2.41, 90 confidence interval [CI] 1.36-4.27, p = 0.0102), but not with increased RFS (HR 1.21, 90 CI 0.74-2.0, p = 0.52) in the overall population. In matched patients, the increased risk of death in case of ALND omission was found only in the Mic cohort (HR 2.88, 90 CI 1.46-5.69), not in the ITC cohort. The risk of recurrence was also significantly increased in the subgroup of matched Mic patients (HR 1.56, 90 CI 0.90-2.73)., Interpretation: A separate analysis of Mic and ITC groups, matched for the determinants of ALND, suggested that patients with Mic had increased recurrence rates and shorter OS when ALND was not performed. Our results are consistent with those of previous studies for patients with ITC but not for those with Mic. Randomised controlled clinical trials are still warranted to show with a high level of evidence if ALND can be safely omitted in patients with micrometastatic disease in SN., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
20. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
- Author
-
Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, Rouzier R, Faure C, Garbay JR, Daraï E, Hudry D, Gimbergues P, Villet R, and Lambaudie E
- Subjects
- Adult, Aged, Aged, 80 and over, Female, France epidemiology, Humans, Lymph Nodes pathology, Lymphatic Metastasis, Middle Aged, Prognosis, Retrospective Studies, Survival Analysis, Triple Negative Breast Neoplasms diagnosis, Axilla pathology, Neoplasm Micrometastasis, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology
- Abstract
Background: Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALNI and especially of small size axillary metastases in early TNBCs., Methods: We analysed in this multicentre study all patients treated for early TNBC in 12 French cancer centres. We explored the correlation between clinicopathological data and ALNI, with a specific focus on the dichotomisation between macrometastases and occult metastases, which is defined as the presence of isolated tumour cells or micrometastases. The prognostic value of ALNI both in terms of disease-free survival (DFS) and overall survival (OS) was also explored., Results: We included 1237 TNBC patients. Five-year DFS and OS were 83.7% and 88.5%, respectively. The identified independent prognostic features for DFS were tumour size >20 mm (hazard ratio (HR)=1.86; 95% CI: 1.11-3.10, P=0.018), lymphovascular invasion (HR=1.69; 95% CI: 1.21-2.34, P=0.002) and ALNI both in case of macrometastases (HR=1.97; 95% CI: 1.38-2.81, P<0.0001) and occult metastases (HR=1.72; 95% CI: 1.1-2.71, P=0.019). DFS and OS were similar between tumours with occult metastases and macrometastases. Tumours presenting at least two pejorative features (out of ALNI, lymphovascular invasion and large tumour size) displayed a significantly poorer DFS in both the training set and validation set, independently of chemotherapy administration. Tumours with no more than one of the above-cited pejorative features had a 5-year OS of ⩾90% vs 70% for other cases (P<0.0001)., Conclusions: Axillary lymph node involvement is a key prognostic feature for early TNBC when isolated tumour cells were identified in lymph nodes. This impact is independent of chemotherapy use.
- Published
- 2016
- Full Text
- View/download PDF
21. Breast cancer in young women: Pathologic features and molecular phenotype.
- Author
-
Sabiani L, Houvenaeghel G, Heinemann M, Reyal F, Classe JM, Cohen M, Garbay JR, Giard S, Charitansky H, Chopin N, Rouzier R, Daraï E, Coutant C, Azuar P, Gimbergues P, Villet R, Tunon de Lara C, and Lambaudie E
- Subjects
- Adult, Breast Neoplasms chemistry, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant, Disease-Free Survival, Female, France, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local etiology, Prognosis, Proportional Hazards Models, Receptor, ErbB-2 analysis, Retrospective Studies, Risk Factors, Age Factors, Breast Neoplasms pathology, Phenotype
- Abstract
Purpose: Controversy exists about the prognosis of breast cancer in young women. Our objective was to describe clinicopathological and prognostic features to improve adjuvant treatment indications., Methods: We conducted a retrospective multi centre study including fifteen French hospitals. Disease-free survival's data, clinical and pathological criteria were collected., Results: 5815 patients were included, 15.6% of them where between 35 and 40 years old and 8.7% below 35. In 94% of the cases, a palpable masse was found in patients ≤35 years old. Triple negative and HER2 tumors were predominantly found in patients ≤35 (22.2% and 22.1%, p < 0.01). A young age ≤40 years (p < 0.001; hazard ratio [HR]: 2.05; 95% confidence limit [CL]: 1.60-2.63) or ≤35 years (p < 0.001; [HR]: 3.86; 95% [CL]: 2.69-5.53) impacted on the indication of chemotherapy. Age ≤35 (p < 0.001; [HR]: 2.01; 95% [CL]: 1.36-2.95) was a significantly negative factor on disease-free survival. Chemotherapy (p < 0.006; [HR]: 0.6; 95% [CL]: 0.40-0.86) and positive hormone receptor status (p < 0.001; [HR]: 0.6; 95% [CL]: 0.54-0.79) appeared to be protector factors. Patients under 36, had a significantly higher rate of local recurrence and distant metastasis compared to patients >35-40 (21.5 vs. 15.4% and 21.8 vs. 12.6%, p < 0.01)., Conclusion: Young women present a different distribution of molecular phenotypes with more luminal B and triple negative tumors with a higher grade and more lymph node involvement. A young age, must be taken as a pejorative prognostic factor and must play a part in indication of adjuvant therapy., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
22. Analysis and modeling of 255 source levels of merchant ships from an acoustic observatory along St. Lawrence Seaway.
- Author
-
Simard Y, Roy N, Gervaise C, and Giard S
- Abstract
An ensemble of 255 spectral source levels (SSLs) of merchant ships were measured with an opportunistic seaway acoustic observatory adhering to the American National Standards Institute/Acoustical Society of America S12.64-2009 standard as much as possible, and deployed in the 350-m deep lower St. Lawrence Seaway in eastern Canada. The estimated SSLs were sensitive to the transmission loss model. The best transmission loss model at the three measuring depths was an empirical in situ function for ranges larger than 300 m, fused with estimates from a wavenumber integration propagation model fed with inverted local geoacoustic properties for [300 to 1 m] ranges. Resulting SSLs still showed a high variability. Uni- and multi-variate analyses showed weak intermingled relations with ship type, length, breadth, draught, speed, age, and other variables. Cluster analyses distinguished six different SSL patterns, which did not correspond to distinctive physical characteristics of the ships. The broadband [20-500 Hz] source levels varied by 30 dB or more within all four 50-m length categories. Common SSL models based on frequency, length and speed failed to unbiasly replicate the observations. This article presents unbiased SSL models that explain 75%-88% of the variance using frequency, ship speed, and three other automatic identification system ship characteristics.
- Published
- 2016
- Full Text
- View/download PDF
23. Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study.
- Author
-
Renaudeau C, Lefebvre-Lacoeuille C, Campion L, Dravet F, Descamps P, Ferron G, Houvenaeghel G, Giard S, Tunon de Lara C, Dupré PF, Fritel X, Ngô C, Verhaeghe JL, Faure C, Mezzadri M, Damey C, and Classe JM
- Subjects
- Adult, Aged, Axilla, False Negative Reactions, Female, Humans, Lymphatic Metastasis, Lymphoscintigraphy, Mastectomy, Segmental, Middle Aged, Postoperative Complications etiology, Prospective Studies, Sentinel Lymph Node diagnostic imaging, Seroma etiology, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma, Ductal, Breast secondary, Carcinoma, Ductal, Breast surgery, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy adverse effects
- Abstract
Aim: Sentinel lymph node (SLN) biopsy was recently recommended after prior breast tumour surgery and lymphadenectomy is not the gold standard anymore for nodal staging after a lesion's removal. The purpose of our study was to evaluate the good practices of use of SLN biopsy in this context., Patients and Methods: From 2006 to 2012, 138 patients having undergone a surgical biopsy without prior diagnosis of an invasive carcinoma with a definitive histological analysis in favour of this diagnosis were included in a prospective observational multicentric study. Each patient had a nodal staging following SLN biopsy with subsequent systematic lymphadenectomy., Results: The detection rate of SLN was 85.5%. The average number of SLNs found was 1.9. The relative detection failure risk rate was multiplied by 4 in the event of an interval of less than 36 days between the SLN biopsy and the previous breast surgery, and by 9 in the event of using a single-tracer detection method. The false negative rate was 6.25%. The prevalence of metastatic axillary node involvement was 11.6%. In 69% of cases only the SLN was metastatic. The post-operative seroma rate was 19.5%., Conclusion: Previous conservative breast tumour surgery does not affect the accuracy of the SLN biopsy. A sufficient interval of greater than 36 days between the two operations could allow to improve the SLN detection rate, although further studies are needed to validate this statement., Clinical Trial Registration Number: NCT00293865., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
- Author
-
Bonneterre J, Prat A, Galván P, Morel P, and Giard S
- Subjects
- Breast Neoplasms genetics, Female, Humans, Prognosis, Retrospective Studies, Risk, Breast Neoplasms drug therapy, Chemotherapy, Adjuvant methods
- Abstract
Purpose In daily clinical practice, the indication for adjuvant chemotherapy (CT) is relatively easy to make in patients with early hormone-receptor-positive (HR+) breast cancer with either very poor or very good clinicopathological prognostic variables. However, this decision is much more difficult in patients with intermediate clinicopathological prognostic variables. Here, we evaluate the value of a gene-expression profile identified by the Prosigna gene signature assay in guiding treatment decision-making in patients with these intermediate features. Methods A consecutive cohort of 577 HR + breast cancer patients surgically treated in a single institution between January 2012 and December 2012 was evaluated. From this population, pre- and post-menopausal patients with intermediate prognosis clinicopathological variables were identified and indication of adjuvant CT in these patients was recorded. The gene signature assay was performed retrospectively in this intermediate risk group. Descriptive statistics are presented. Results Among 96 intermediate-risk patients, 64 postmenopausal patients underwent gene signature testing. Subtype distribution was as follows: Luminal A (N = 33; 51.6%), Luminal B (N = 31; 48.4%). Risk of recurrence (ROR) distribution was as follows: ROR-low (n = 16; 25%); ROR-intermediate (N = 26; 40.6%); and ROR-high (N = 22; 34.4%). CT was subsequently administered in 18.7%, 53.8% and 59.0% of the ROR-low, ROR-intermediate and ROR-high groups, respectively. With the use of the gene signature assay, 59.4% of the intermediate cases were re-classified to either ROR-low or ROR-high risk categories. In the ROR-intermediate group, 11/26 patients (42.3%) had Luminal A and 15/26 (57.7%) had Luminal B. Due to follow-up time constraints, no patient outcome results were evaluated. Conclusion The gene signature assay provides clinically useful information and improved treatment decision-making in patients with intermediate risk based on clinicopathological factors. Determining the patient's intrinsic subtype and ROR can aid clinicians in deciding whether CT should be indicated.
- Published
- 2016
- Full Text
- View/download PDF
25. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
- Author
-
Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, Charytansky H, Rouzier R, Daraï E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, Chauvet MP, Goncalves A, and Lambaudie E
- Subjects
- Adult, Aged, Axilla, Biomarkers, Tumor analysis, Breast Neoplasms chemistry, Breast Neoplasms mortality, Breast Neoplasms surgery, Chemotherapy, Adjuvant, Female, France, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymph Nodes chemistry, Lymph Nodes surgery, Lymphatic Metastasis, Mastectomy adverse effects, Mastectomy mortality, Middle Aged, Multivariate Analysis, Neoplasm Micrometastasis, Odds Ratio, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Triple Negative Breast Neoplasms chemistry, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms surgery, Breast Neoplasms pathology, Lymph Nodes pathology, Sentinel Lymph Node Biopsy
- Abstract
Background: The rate of axillary recurrence (AR) after sentinel lymph node biopsy is usually low but few studies investigated its impact on survival. Our aim was to determine the rate and predictive factors of AR in a large cohort of breast cancer patients and its impact on survival., Patients and Methods: From 1999 to 2013, 14,095 patients who underwent surgery for clinically N0 previously untreated breast cancer and had sentinel lymph node biopsy were analysed. A simplified score predictive of AR was established., Results: Median follow-up was 55.2 months. AR was observed in 0.51% of cases, with a median time to onset of 43.4 months. In multivariate analysis, the occurrence of AR was significantly correlated with grade 2 or 3 disease, absence of radiotherapy and tumour subtype (hormonal receptor [HR]- / human estrogen receptor [HER]+). AR rates were 1% for triple-negative tumours, 2.8% for HER2-positive tumours, 0.4% for luminal A tumours, 0.9% for HER2-negative luminal B tumours, and 0.5% for HER2-positive luminal B tumours. A simplified score predictive of the occurrence of AR was established. Patients could be divided into three different score groups (p < 0.0001). In multivariate analysis, overall survival was significantly lower in cases of AR (p < 0.0001), age >50, lymphovascular invasion, grade 3 disease, sentinel node (SN) macrometastases, tumour size >20 mm, absence of chemotherapy and triple-negative phenotype. Survival in patients with AR was significantly lower in case of early-onset (2 years) AR (p = 0.017)., Conclusions: Isolated AR is more common in Her2-positive/HR-negative triple-negative tumours with a more severe prognosis in triple-negative and Her2-positive/HR-negative tumours, and represents an independent adverse factor justifying an indication for systemic treatment for AR treatment. However, the benefit of any systemic treatment remains to be proven., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
26. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial.
- Author
-
Houpeau JL, Chauvet MP, Guillemin F, Bendavid-Athias C, Charitansky H, Kramar A, and Giard S
- Subjects
- Aged, Breast Neoplasms pathology, Carcinoma secondary, Feasibility Studies, Female, France, Humans, Middle Aged, Prospective Studies, Radiopharmaceuticals, Breast Neoplasms surgery, Carcinoma surgery, Contrast Media, Dextrans, Magnetite Nanoparticles, Magnetometry instrumentation, Sentinel Lymph Node Biopsy methods
- Abstract
Background and Objectives: The French Sentimag feasibility trial evaluated a new method for the localization of breast cancer sentinel lymph node (SLN) using Sienna+®, superparamagnetic iron oxide particles, and Sentimag® detection in comparison to the standard technique (isotopes ± blue dye)., Methods: We conducted a prospective multicentric paired comparison trial on 115 patients. SLN localization was performed using both the magnetic technique and the standard method. Detection rate and concordance between magnetic and standard tracers were calculated. Post-operative complications were assessed after 30 days., Results: Results are based on 108 patients. SLN identification rate was 98.1% [93.5-99.8] for both methods, 97.2% [92.1-99.4] for Sienna+® and 95.4% [89.5-98.5] for standard technique. A mean of 2.1 SLNs per patient was removed. The concordance rate was 99.0% [94.7-100.0%] per patient and 97.4% [94.1-99.2] per node. Forty-six patients (43.4%) had nodal involvement. Among involved SLNs, concordance rate was 97.7% [88.0-99.9] per patient and 98.1% [90.1-100.0] per node., Conclusions: This new magnetic tracer is a feasible method and a promising alternative to the isotope. It could offer benefits for ambulatory surgery or sites without nuclear medicine departments. J. Surg. Oncol. 2016;113:501-507. © 2016 Wiley Periodicals, Inc., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
27. A Seaway Acoustic Observatory in Action: The St. Lawrence Seaway.
- Author
-
Simard Y, Roy N, Gervaise C, and Giard S
- Subjects
- Canada, Ships, Acoustics
- Abstract
A setup for measuring spectral source levels (SSLs) of ships transiting along a seaway, the traffic density and shipping noise, is presented. The results feed shipping-noise modeling that reproduces the actual in situ observations to map shipping-noise variability over space and time for investigating its effects on aquatic organisms. The ship's SSL databank allows sorting the different contributors to total shipping noise for assisting in exploring mitigation approaches (e.g., fleet composition, rerouting). Such an acoustic observatory was deployed since November 2012 for a complete annual cycle of measurements in the deep downstream part of the St. Lawrence Seaway.
- Published
- 2016
- Full Text
- View/download PDF
28. [Lobular invasive breast cancer prognostic factors: About 940 patients].
- Author
-
Jauffret C, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Bélichard C, Faure C, Darai É, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Goncalves A, and Lambaudie É
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Axilla, Disease-Free Survival, Female, France, Humans, Lymph Node Excision, Lymph Nodes pathology, Middle Aged, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Breast Neoplasms pathology, Carcinoma, Lobular pathology, Lymphatic Metastasis pathology
- Abstract
Objectives: To assess the prognostic factors of T1 and T2 infiltrating lobular breast cancers, and to investigate predictive factors of axillary lymph node involvement., Methods: This is a retrospective multicentric study, conducted from 1999 to 2008, among 13 french centers. All data concerning patients with breast cancer who underwent a primary surgical treatment including a sentinel lymph node procedure have been collected (tumors was stage T1 or T2). Patients underwent partial or radical mastectomy. Axillary lymph node dissection was done systematically (at the time of sentinel procedure evaluation), or in case of sentinel lymph node involvement. Among all the 8100 patients, 940 cases of lobular infiltrating tumors were extracted. Univariate analysis was done to identify significant prognosis factors, and then a Cox regression was applied. Analysis interested factors that improved disease free survival, overall survival and factors that influenced the chemotherapy indication. Different factors that may be related with lymph node involvement have been tested with univariate than multivariate analysis, to highlight predictive factors of axillary involvement., Results: Median age was 60 years (27-89). Most of patients had tumours with a size superior to 10mm (n=676, 72%), with a minority of high SBR grade (n=38, 4%), and a majority of positive hormonal status (n = 880, 93, 6%). The median duration of follow-up was 59 months (1-131). Factors significantly associated with decreased disease free survival was histological grade 3 (hazard ratio [HR]: 3,85, IC 1,21-12,21), tumour size superior to 2cm (HR: 2,85, IC: 1,43-5,68) and macrometastatic lymph node status (HR: 3,11, IC: 1,47-6,58). Concerning overall survival, multivariate analysis demonstrated a significant impact of age less than 50 years (HR: 5,2, IC: 1,39-19,49), histological grade 3 (HR: 5,03, IC: 1,19-21,25), tumour size superior to 2cm (HR: 2,53, IC: 1,13-5,69). Analysis concerning macrometastatic lymph node status nearly reached significance (HR: 2,43, IC: 0,99-5,93). There was no detectable effect of chemotherapy regarding disease free survival (odds ratio [OR] 0,8, IC: 0,35-1,80) and overall survival (OR: 0,72, IC: 0,28-1,82). Disease free survival was similar between no axillary invasion (pN0) and isolated tumor cells (pNi+), or micrometastatic lymph nodes (pNmic). There were no difference neither between one or more than one macromatastatic lymph node. But disease free survival was statistically worse for pN1 compared to other lymph node status (pN0, pNi+ or pNmic). Factors associated with lymph node involvement after logistic regression was: age from 51 to 65 years (OR: 2,1, IC 1,45-3,04), age inferior to 50 years (OR 3,2, IC: 2,05-5,03), Tumour size superior to 2cm (OR 4,4, IC: 3,2-6,14), SBR grading 2 (OR 1,9, IC: 1,30-2,90) and SBR grade 3 (OR 3,5, IC: 1,61-7,75)., Conclusion: The analysis of this series of 940 T1 and T2 lobular invasive breast carcinomas offers several information: factors associated with axillary lymph node involvement are age under 65 years, tumor size greater than 20mm, and a SBR grade 2 or 3. The same factors were significantly associated with the OS and DFS. The macrometastatic lymph node involvement has a significant impact on DFS and OS, which is not true for isolated cells and micrometastases, which seem to have the same prognosis as pN0., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
29. Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.
- Author
-
Clough KB, Acosta-Marín V, Nos C, Alran S, Rouanet P, Garbay JR, Giard S, Verhaeghe JL, Houvenaeghel G, Flipo B, Dauplat J, Dorangeon PH, Classe JM, Rouzier R, and Bonnier P
- Subjects
- Breast Neoplasms pathology, Cancer Care Facilities statistics & numerical data, Female, France, Hospitals, Private statistics & numerical data, Hospitals, Public statistics & numerical data, Humans, Neoadjuvant Therapy statistics & numerical data, Retrospective Studies, Surgery, Plastic, Surveys and Questionnaires, Breast Neoplasms drug therapy, Breast Neoplasms surgery, Chemotherapy, Adjuvant statistics & numerical data, Mastectomy, Segmental statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data
- Abstract
Background: The current retrospective study was intended to obtain up-to-date and comprehensive data on surgical practice for breast cancer throughout France, including neoadjuvant chemotherapy (NAC) and the more recent surgical techniques of oncoplastic surgery (OPS)., Methods: In June 2011, e-mail surveys were sent to 33 nationally renowned breast cancer surgeons from French public or private hospitals. The questionnaire focused on all the new cases of breast cancer treated in 2010. It included questions regarding surgical practices, with special emphases on NAC and OPS and other surgical characteristics., Results: The overall response rate for the survey was 72.7 %. The total number of breast cancer cases from the survey was 13,762, which constitutes 26.2 % of the total incidence in 2010. Breast-conserving surgery (BCS) was performed for 71.0 % of the patients, and the results were similar throughout the types of practices. Of these patients, 13.9 % received OPS, either upfront or after NAC. Mastectomy was performed for 29.0 % of the patients, which is consistent with French official numbers. Among all patients, 16.3 % underwent surgery after NAC., Conclusion: To the authors' knowledge, there are no publications of national figures on NAC or OPS rates to date. They are convinced that this study offers real-life surgical care information on a large population and covers France's breast cancer surgical landscape. Mastectomy rates in France remain stable and consistent with those in other European countries. However, additional large-scale retrospective studies are required to confirm these figures and further explore NAC and OPS rates as well as surgical practice characteristics.
- Published
- 2015
- Full Text
- View/download PDF
30. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.
- Author
-
Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, and Reis-Filho JS
- Subjects
- Cell Line, Tumor, Chromosomal Proteins, Non-Histone genetics, Chromosomal Proteins, Non-Histone metabolism, Female, Gene Dosage, Humans, MCF-7 Cells, Mutation, Signal Transduction, Transcription Factor TFIIIB genetics, Transcription Factor TFIIIB metabolism, Breast Neoplasms genetics, Gene Amplification, Receptor, ErbB-2 genetics
- Abstract
Background: HER2 is overexpressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and predictive marker of response to anti-HER2 agents. In a subset of these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clinically challenging scenarios. Currently, breast cancers with HER2 amplification/overexpression in just over 10% of cancer cells are considered HER2-positive for clinical purposes; however, it is unclear as to whether the HER2-negative components of such tumors would be driven by distinct genetic alterations. Here we sought to characterize the pathologic and genetic features of the HER2-positive and HER2-negative components of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of potential driver genetic alterations in the HER2-negative components of these cases., Results: We separately analyzed the HER2-negative and HER2-positive components of 12 HER2 heterogeneous breast cancers using gene copy number profiling and massively parallel sequencing, and identified potential driver genetic alterations restricted to the HER2-negative cells in each case. In vitro experiments provided functional evidence to suggest that BRF2 and DSN1 overexpression/amplification, and the HER2 I767M mutation may be alterations that compensate for the lack of HER2 amplification in the HER2-negative components of HER2 heterogeneous breast cancers., Conclusions: Our results indicate that even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distributed within a cancer, and that the HER2-negative components are likely driven by genetic alterations not present in the HER2-positive components, including BRF2 and DSN1 amplification and HER2 somatic mutations.
- Published
- 2015
- Full Text
- View/download PDF
31. [Non-palpable breast cancer malignant on needle core biopsy and no malignancy in surgical excision: how to manage?].
- Author
-
Cheurfa N and Giard S
- Subjects
- Adult, Aged, Biopsy, Large-Core Needle, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast surgery, Carcinoma, Intraductal, Noninfiltrating pathology, Carcinoma, Intraductal, Noninfiltrating surgery, Databases, Factual, False Positive Reactions, Female, Humans, Middle Aged, Treatment Failure, Breast Neoplasms pathology, Breast Neoplasms surgery, Mastectomy, Segmental
- Abstract
Objective: Despite the standard management of non-palpable breast cancer (needle core biopsy diagnostic, accurate preoperative localization), there are differences in some cases between the malignant histo-pathological finding in diagnostic biopsy results and negative histo-pathological finding after surgical excision. The aim of this study is to evaluate this incidence and classifying them under three category: failure of surgical excision after preoperative identification; removal of the tumor was already completed by percutaneous biopsy; percutaneous biopsy true false positive., Patients and Methods: We conducted a study based on prospective database, all patients included in this study had partial mastectomy for ductal carcinoma in-situ or invasive cancer which was diagnosed by needle core biopsy and normal/benign after surgery., Results: Regarding the partial mastectomy, 1863 was performed in the last three years in our center. Thirty-seven patients (2%) correspond our study criteria. After discussion of cases in our multidisciplinary reunion, 6 patients (16%) were considered as failure of surgical excision, 26 patients (70%) as true removal of the whole lesion in the core, and 5 patients (13%) as true false-positive cores., Discussion and Conclusion: This is the first study witch investigate all factors that influence the results of negative final histo-pathological finding of surgical excision of the tumor after malignant diagnostic needle core biopsy. This rare situation need a multidisciplinary meeting to analyse all the steps of management and to determine causes of those false results and try to find adequate management to solve this problem., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
- Author
-
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, and Berriolo-Riedinger A
- Subjects
- Adult, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Ductal, Breast secondary, Chemotherapy, Adjuvant, Combined Modality Therapy, Docetaxel, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Radiopharmaceuticals, Survival Rate, Taxoids administration & dosage, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms diagnostic imaging, Carcinoma, Ductal, Breast diagnostic imaging, Fluorodeoxyglucose F18, Neoadjuvant Therapy, Positron-Emission Tomography, Receptor, ErbB-2 metabolism
- Abstract
Background: An effective and well tolerated treatment is needed for patients with early HER2-positive breast cancer who do not achieve a pathological complete response after neoadjuvant therapy. The AVATAXHER trial aimed to predict pathological complete response early with the use of PET and to investigate whether the addition of bevacizumab could improve the proportion of patients achieving a pathological complete response in patients unlikely to respond to treatment., Methods: AVATAXHER was a randomised, open-label, non-comparative, multicentre phase 2 study that enrolled women (≥18 years of age) with early-stage HER2-positive breast cancer from 26 oncology centres in France. Patients initially received two cycles of neoadjuvant docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course). Before the first and second cycles, [(18)F]-fluorodeoxyglucose (FDG) PET was done and the change in standardised uptake value was used to predict pathological complete response in each patient. Patients who were predicted to be responders on PET continued to receive standard therapy. Predicted non-responders were randomly assigned (2:1) to receive four cycles of docetaxel (100 mg/m(2) intravenously every 3 weeks) and trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A) or continue on docetaxel plus trastuzumab alone (group B). Randomisation was open label and was done by an adaptive minimisation method. Although investigators and patients were aware of group assignment, the anatomo-pathologist in charge of centralised review of surgical samples and lymph nodes was masked to treatment assignment. The primary endpoint was centrally assessed pathological complete response according to the Chevallier classification. Efficacy analyses were done in the intention-to-treat population. Safety analyses in this Article were done on all patients who received at least one dose of treatment starting from cycle 3. Survival outcomes are not yet mature. This study is registered with ClinicalTrials.gov (NCT01142778) and EUDRACT (2009-013410-26)., Findings: Between May 19, 2010, and Oct 1, 2012, 152 patients were recruited for the study. Ten patients were subsequently excluded, leaving 142 patients in the intention-to-treat population. Of these 142 patients, 69 were predicted by [(18)F]-FDG PET to be treatment responders after two cycles of treatment. The 73 predicted non-responders were randomly assigned to group A (n=48) and group B (n=25). Pathological complete responses were noted in 37 (53·6%, 95% CI 41·2-65·7) of the PET responders, 21 (43·8%, 29·5-58·8) of those in group A, and six (24·0%, 9·4-45·1) of those in group B. Incidences of grade 3-4 adverse events were similar in all three groups. The most common grade 3-4 adverse events were neutropenia (four in PET responders, five in group A, and three in group B), febrile neutropenia (one, three, and one, respectively), and myalgia (four, none, and one, respectively). Overall, 24 serious adverse events were reported in 15 patients (PET responders: nine events in four [6%] of 67 patients; group A: 14 events in ten [21%] of 47 patients; group B: one event in one [4%] of 25 patients). No deaths occurred during the study., Interpretation: In patients with HER2-positive breast cancer, early PET assessment can help to identify non-responders to neoadjuvant docetaxel plus trastuzumab therapy. In these patients, the addition of bevacizumab can increase the proportion of patients achieving a pathological complete response. This potential new role for PET and the activity of bevacizumab in this setting need to be confirmed in larger phase 3 trials., Funding: Roche France., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
33. Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts.
- Author
-
Ziouèche-Mottet A, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Belichard C, Faure C, Chéreau Ewald E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Tallet A, Bannier M, Minsat M, Lambaudie E, and Resbeut M
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms diagnosis, Cohort Studies, Combined Modality Therapy, Female, Humans, Middle Aged, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Retrospective Studies, Survival Analysis, Young Adult, Breast Neoplasms radiotherapy, Breast Neoplasms surgery
- Abstract
Background: We wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence., Methods: We undertook a retrospective study examining two cohorts. The first cohort was multicentric (G3S) and contained 7580 patients. The second cohort was monocentric (cohort 2) comprising 4445 patients. All patients underwent conservative surgery followed by external radiotherapy for invasive breast cancer (T0-T3, N0-N1) between 1980 and 2005. Within each cohort, two groups were isolated according to the inclusion criteria of the TARGIT A study (T group) and RIOP trial (R group).In the multicentric cohort (G3S) eligible patients for TARGIT A and RIOP trials were T1E and R1E subgroups, respectively. In cohort number 2, the corresponding subgroups were T2E and R2E. Similarly, non-eligible patients were T1nE, R1nE and T2nE, and R2nE.The eligible groups in the TARGIT A study that were not eligible in the RIOP trial (TE-RE) were also studied. The proportion of patients eligible for TARGIT was calculated according to the criteria of each study. A comparison was made of the 5-year survival without local or locoregional recurrence between the TE versus TnE, RE versus RnE, and RE versus (TE-RE) groups., Results: In G3S and cohort 2, the proportion of patients eligible for TARGIT was, respectively, 53.2% and 33.9% according the criteria of the TARGIT A study, and 21% and 8% according the criteria of the RIOP trial. Survival without five-year locoregional recurrence was significantly different between T1E and T1nE groups (97.6% versus 97% [log rank=0.009]), R1E and R1nE groups (98% versus 97.1% [log rank=0.011]), T2E and T2nE groups (96.6% versus 93.1% [log rank<0. 0001]) and R2E and R2nE groups (98.6% versus 94% [log rank=0.001]). In both cohorts, no significant difference was found between RE and (TE-RE) groups., Conclusions: Almost 50% of T0-2 N0 patients could be eligible for TARGIT.
- Published
- 2014
- Full Text
- View/download PDF
34. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study.
- Author
-
Houvenaeghel G, Classe JM, Garbay JR, Giard S, Cohen M, Faure C, Hélène C, Belichard C, Uzan S, Hudry D, Azuar P, Villet R, Penault Llorca F, Tunon de Lara C, Goncalves A, and Esterni B
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Carcinoma, Ductal, Breast mortality, Carcinoma, Lobular mortality, Female, Follow-Up Studies, France, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Survival Analysis, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular pathology, Neoplasm Micrometastasis
- Abstract
To define the prognostic value of isolated tumor cells (ITC), micrometastases (pN1mi) and macrometastases in early stage breast cancer (ESBC). We conducted a retrospective multicenter cohort study at 13 French sites. All the eligible patients who underwent SLNB from January 1999 to December 2008 were identified, and appropriate data were extracted from medical records and analyzed. Among 8001 patients, including 70% node-negative (n = 5588), 4% ITC (n = 305), 10% pN1mi (n = 794) and 16% macrometastases (n = 1314) with a median follow-up of 61.3 months, overall survival (OS) and recurrence-free survival (RFS) rates at 84 months were not statistically different in ITC or pN1mi compared to tumor-free nodes. Axillary recurrence (AR) was significantly more frequent in ITC (1.7%) and pN1mi (1.5%) compared to negative nodes (0.6%). Survival and AR rates of single macrometastases were not different from those of ITC or pN1mi. In case of 2 macrometastases or more, survival rates decreased and recurrence rates increased significantly. Micrometastases and ITC do not have a negative prognostic value. Single macrometastases might have an intermediate prognostic value while 2 macrometastases or more are associated with poorer prognosis., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
35. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.
- Author
-
Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H, Cohen M, Belichard C, Faure C, Uzan S, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Lambaudie E, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, and Esterni B
- Subjects
- Adjuvants, Pharmaceutic therapeutic use, Cohort Studies, Disease-Free Survival, Female, Humans, Lymphatic Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Retrospective Studies, Risk Factors, Treatment Outcome, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Receptor, ErbB-2 metabolism
- Abstract
Background: A subgroup of T1N0M0 breast cancer (BC) carries a high potential of relapse, and thus may require adjuvant systemic therapy (AST)., Patients and Methods: Retrospective analysis of all patients with T1 BC, who underwent surgery from January 1999 to December 2009 at 13 French sites. AST was not standardized., Results: Among 8100 women operated, 5423 had T1 tumors (708 T1a, 2208 T1b and 2508 T1c 11-15 mm). T1a differed significantly from T1b tumors with respect to several parameters (lower age, more frequent negative hormonal status and positive HER2 status, less frequent lymphovascular invasion), exhibiting a mix of favorable and poor prognosis factors. Overall survival was not different between T1a, b or c tumors but recurrence-free survival was significantly higher in T1b than in T1a tumors (P = 0.001). In multivariate analysis, tumor grade, hormone therapy and lymphovascular invasion were independent prognostic factors., Conclusion: Relatively poor outcome of patients with T1a tumors might be explained by a high frequency of risk factors in this subgroup (frequent negative hormone receptors and HER2 overexpression) and by a less frequent administration of AST (endocrine treatment and chemotherapy). Tumor size might not be the main determinant of prognosis in T1 BC.
- Published
- 2014
- Full Text
- View/download PDF
36. Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases.
- Author
-
Cutuli B, Lemanski C, Le Blanc-Onfroy M, de Lafontan B, Cohen-Solal-Le-Nir C, Fondrinier E, Mignotte H, Giard S, Charra-Brunaud C, Auvray H, Gonzague-Casabianca L, Quétin P, and Fay R
- Subjects
- Adult, Axilla, Breast Neoplasms therapy, Carcinoma in Situ therapy, Carcinoma, Ductal, Breast therapy, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Mammography, Mastectomy statistics & numerical data, Mastectomy, Segmental, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Neoplasm Recurrence, Local therapy, Prognosis, Radiotherapy, Adjuvant, Risk Factors, Salvage Therapy, Breast Neoplasms pathology, Carcinoma in Situ pathology, Carcinoma, Ductal, Breast pathology, Neoplasm Recurrence, Local pathology
- Abstract
Purpose: Ductal carcinoma in situ overall prognosis is excellent, but after breast conserving surgery, with or without radiotherapy, local recurrences can lead to locoregional or distant evolution and death. However, there are few data on optimal local recurrences treatment and long-term impact on survival., Patients and Methods: This study included 195 women treated from 1985 to 1996 by conservative surgery (CS) or conservative surgery followed by radiotherapy (CS+RT), presenting local recurrences, with a 156-month median follow-up., Results: Eighty-two out of 195 (42%) local recurrences were non-invasive (in situ) and 113 (58%) invasive. In situ local recurrence was discovered by mammography in 80.5% of the cases versus 47.5% for invasive local recurrence (P=0.0001). Salvage mastectomy was used in 53% of the cases after conservative surgery and 75% after conservative surgery followed by radiotherapy. The axillary nodal involvement rates were 11.8% and 25.8% among 17 and 62 patients with in situ and invasive local recurrences. Among 113 patients with invasive local recurrences and 82 with in situ local recurrences, 19 (16.8%) and three (3.6%) developed metastases, respectively. Among invasive local recurrences, comedocarcinoma subtype was highly predictive of subsequent metastases (32% versus 4.4%, P<0.0007)., Conclusion: Invasive local recurrence after ductal carcinoma in situ treatment could be a dramatic event, fully changing long-term prognosis. Early mammographic local recurrence diagnosis (if possible still at non-invasive stage) seems essential to avoid or minimize metastatic risk. Mastectomy remains the safest option but, in some cases, a new conservative approach could be discussed., (Copyright © 2013. Published by Elsevier SAS.)
- Published
- 2013
- Full Text
- View/download PDF
37. Pure tubular carcinoma of the breast and sentinel lymph node biopsy: a retrospective multi-institutional study of 234 cases.
- Author
-
Dejode M, Sagan C, Campion L, Houvenaeghel G, Giard S, Rodier JF, Ferron G, Jaffre I, Levêque J, Bendavid C, Dravet F, Marchal F, Bordes V, Faure C, Tunon de Lara C, and Classe JM
- Subjects
- Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Axilla, Female, Humans, Lymphatic Metastasis diagnosis, Middle Aged, Multivariate Analysis, Prognosis, Retrospective Studies, Breast Neoplasms pathology, Breast Neoplasms surgery, Carcinoma, Ductal, Breast pathology, Lymph Nodes pathology, Mastectomy, Segmental, Sentinel Lymph Node Biopsy
- Abstract
Background: Pure Tubular Carcinoma (PTC) of the breast is a rare histological subtype of invasive breast cancer characterized by a low rate of lymph node involvement. Currently there is no consensus on less surgical axillary node staging according to this histological subtype., Methods: We performed a retrospective multi-institutional study. Inclusion criteria were PTC, sentinel lymph node detection (SLND) and conservative breast surgery., Results: From January 1999 to December 2006, 234 patients were included in the study from 9 institutions. The median pathological tumor size was 9.59 (1-22) mm. SLN were successfully detected in 98% (229/234) of patients. Among the 234 patients, a macrometastasis was found in 6 cases (2.5%), micrometastasis in 15 cases (6.4%), and isolated cells in 2 cases (0.8%). In the case of patients with SLND macrometastasis, half of them had macrometastasis in the complementary axillary lymphadenectomy, and none in the case of SLN only micrometastasis or isolated cells. Of the 122 patients with a pathological tumor size <10 mm, none had sentinel node macrometastasis. According to a multivariate analysis, pathological tumor size (>10 mm) was the only parameter significatively linked to the risk of lymph node involvement (p = 0.007)., Conclusion: In a large multi-institutional series with SLND, we have shown that the risk of axillary lymph node involvement in PTC is very low. In the case of PTC <10 mm, we suggest that surgical axillary evaluation, even with SLND, may not be warranted., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
38. [Radiotherapy of invasive breast cancer: French national guidelines].
- Author
-
Besnard S, Cutuli B, Fourquet A, Giard S, Hennequin C, Leblanc-Onfroy M, Mazeau-Woynar V, and Verdoni L
- Subjects
- Antineoplastic Agents therapeutic use, Breast pathology, Breast Neoplasms pathology, Dose Fractionation, Radiation, Female, Fibrosis, France, Humans, Lymph Nodes radiation effects, Mastectomy, Mastectomy, Segmental, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Recurrence, Local prevention & control, Organs at Risk, Radiotherapy, Adjuvant, Risk Factors, Breast Neoplasms radiotherapy
- Abstract
The French National Cancer Institute (INCa) and Société française de sénologie et pathologie mammaire (SFSPM), in collaboration with a multidisciplinary experts group, have published the French national clinical practice guidelines on a selection of 11 currently debated questions regarding the management of invasive breast cancer. Those guidelines are based on a comprehensive analysis of the current published evidence dealing with those issues, secondly reviewed by 100 reviewers. Radiotherapy was concerned by five of the 11 questions: indications for the boost after whole gland irradiation; hypofractionated radiotherapy; partial breast irradiation; indications for mammary internal nodes irradiation, and indications of radiotherapy after neo-adjuvant chemotherapy., (Copyright © 2012. Published by Elsevier SAS.)
- Published
- 2012
- Full Text
- View/download PDF
39. Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients 'on behalf of the Group of Surgeons from the French Unicancer Federation'.
- Author
-
Classe JM, Baffert S, Sigal-Zafrani B, Fall M, Rousseau C, Alran S, Rouanet P, Belichard C, Mignotte H, Ferron G, Marchal F, Giard S, Tunon de Lara C, Le Bouedec G, Cuisenier J, Werner R, Raoust I, Rodier JF, Laki F, Colombo PE, Lasry S, Faure C, Charitansky H, Olivier JB, Chauvet MP, Bussières E, Gimbergues P, Flipo B, Houvenaeghel G, Dravet F, and Livartowski A
- Subjects
- Aged, Algorithms, Axilla pathology, Breast Neoplasms diagnosis, Breast Neoplasms surgery, Carcinoma diagnosis, Carcinoma surgery, Costs and Cost Analysis, Disease Progression, Female, France, General Surgery organization & administration, Humans, Length of Stay economics, Length of Stay statistics & numerical data, Lymph Node Excision methods, Lymph Nodes pathology, Lymph Nodes surgery, Lymphatic Metastasis diagnosis, Medical Oncology organization & administration, Middle Aged, Neoplasm Staging economics, Prospective Studies, Societies, Medical, Breast Neoplasms economics, Breast Neoplasms pathology, Carcinoma economics, Carcinoma pathology, Lymph Node Excision economics, Sentinel Lymph Node Biopsy economics
- Abstract
Background: Our objective was to assess the global cost of the sentinel lymph node detection [axillary sentinel lymph node detection (ASLND)] compared with standard axillary lymphadenectomy [axillary lymph node dissection (ALND)] for early breast cancer patients., Patients and Methods: We conducted a prospective, multi-institutional, observational, cost comparative analysis. Cost calculations were realized with the micro-costing method from the diagnosis until 1 month after the last surgery., Results: Eight hundred and thirty nine patients were included in the ASLND group and 146 in the ALND group. The cost generated for a patient with an ASLND, with one preoperative scintigraphy, a combined method for sentinel node detection, an intraoperative pathological analysis without lymphadenectomy, was lower than the cost generated for a patient with lymphadenectomy [€ 2947 (σ = 580) versus € 3331 (σ = 902); P = 0.0001]., Conclusion: ASLND, involving expensive techniques, was finally less expensive than ALND. The length of hospital stay was the cost driver of these procedures. The current observational study points the heterogeneous practices for this validated and largely diffused technique. Several technical choices have an impact on the cost of ASLND, as intraoperative analysis allowing to reduce rehospitalization rate for secondary lymphadenectomy or preoperative scintigraphy, suggesting possible savings on hospital resources.
- Published
- 2012
- Full Text
- View/download PDF
40. Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: nomogram validation and comparison with other models.
- Author
-
Houvenaeghel G, Bannier M, Nos C, Giard S, Mignotte H, Jacquemier J, Martino M, Esterni B, Belichard C, Classe JM, Tunon de Lara C, Cohen M, Payan R, Blanchot J, Rouanet P, Penault-Llorca F, Bonnier P, Fournet S, Agostini A, Marchal F, and Garbay JR
- Subjects
- Cohort Studies, Female, Humans, Multivariate Analysis, Nomograms, Reproducibility of Results, Risk, Sentinel Lymph Node Biopsy, Breast Neoplasms diagnosis, Lymphatic Metastasis, Neoplasm Micrometastasis diagnosis
- Abstract
Purpose: The risk of non sentinel node (NSN) involvement varies in function of the characteristics of sentinel nodes (SN) and primary tumor. Our aim was to determine and validate a statistical tool (a nomogram) able to predict the risk of NSN involvement in case of SN micro or sub-micrometastasis of breast cancer. We have compared this monogram with other models described in the literature., Methods: We have collected data on 905 patients, then 484 other patients, to build and validate the nomogram and compare it with other published scores and nomograms., Results: Multivariate analysis conducted on the data of the first cohort allowed us to define a nomogram based on 5 criteria: the method of SN detection (immunohistochemistry or by standard coloration with HES); the ratio of positive SN out of total removed SN; the pathologic size of the tumor; the histological type; and the presence (or not) of lympho-vascular invasion. The nomogram developed here is the only one dedicated to micrometastasis and developed on the basis of two large cohorts. The results of this statistical tool in the calculation of the risk of NSN involvement is similar to those of the MSKCC (the similarly more effective nomogram according to the literature), with a lower rate of false negatives., Conclusion: this nomogram is dedicated specifically to cases of SN involvement by metastasis lower or equal to 2 mm. It could be used in clinical practice in the way to omit ALND when the risk of NSN involvement is low., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
41. [Breast implants and health alert PIP: experience of the regional cancer center of Lille].
- Author
-
Carillon MA, Giard S, Emmanuelli V, Houpeau JL, Ceugnart L, and Chauvet MP
- Subjects
- Cancer Care Facilities, Device Removal statistics & numerical data, Female, France, Humans, Implant Capsular Contracture diagnosis, Magnetic Resonance Imaging standards, Mammaplasty instrumentation, Middle Aged, Prosthesis Failure, Retrospective Studies, Sensitivity and Specificity, Silicone Gels, Ultrasonography, Mammary standards, Breast Implants adverse effects
- Abstract
Introduction: On March 30, 2010, Afssaps issued a health alert concerning breast implants brand PIP, after identifying a rupture rate higher than for other manufacturers. This alert asking the recall of all concerned patients with, according to the clinical examination, ultrasound and the desire of the patient, the possibility of explantation. We focus on PIP implanted in Oscar-Lambret center in Lille., Materials and Patients: A retrospective study on all patients carrying breast prosthesis PIP implanted in the Oscar-Lambret center. We are interested in the rate of patients who chose clinical and ultrasound monotoring, explantation rates, and prosthetic rupture., Results: Thirty-three PIP (in 31 patients) have been implanted in the center between May 2, 2006 and March 9, 2010. The mean age of implants was 15.35 months. We realized eight explants, and found three intracapsular rupture. Two of three rupture were symptomatic., Conclusion: The majority of patients chose surveillance. Our short series does not give precise information about their risk of prosthetic failure, a national register should be established. The literature illustrates the low sensitivity of ultrasonography in the diagnosis of intracapsular rupture and the superiority of MRI. In the context of a health alert, could we propose a monitoring tool implant breast MRI in order to minimize the rate of patients carrying a ruptured implant (false negative).
- Published
- 2012
- Full Text
- View/download PDF
42. Is adjuvant chemotherapy useful in lobular breast cancer patients?
- Author
-
Liem X, Baranzelli MC, Penel N, Giard S, and Bonneterre J
- Subjects
- Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Disease-Free Survival, Epirubicin administration & dosage, Female, Fluorouracil administration & dosage, Humans, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Lobular drug therapy
- Published
- 2011
- Full Text
- View/download PDF
43. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
- Author
-
Avril A, Le Bouëdec G, Lorimier G, Classe JM, Tunon-de-Lara C, Giard S, MacGrogan G, Debled M, Mathoulin-Pélissier S, and Mauriac L
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal therapeutic use, Axilla, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Ductal, Breast mortality, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast secondary, Carcinoma, Ductal, Breast therapy, Carcinoma, Lobular mortality, Carcinoma, Lobular pathology, Carcinoma, Lobular secondary, Carcinoma, Lobular therapy, Chemotherapy, Adjuvant, Disease-Free Survival, Early Termination of Clinical Trials, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lymph Nodes pathology, Lymphatic Metastasis, Middle Aged, Neoplasm Staging, Postmenopause, Radiotherapy, Adjuvant, Survival Rate, Tamoxifen therapeutic use, Breast Neoplasms therapy, Lymph Node Excision adverse effects, Mastectomy, Modified Radical, Mastectomy, Segmental, Neoplasm Recurrence, Local
- Abstract
Background: Axillary lymph node clearance (ALNC) improves locoregional control and provides prognostic information for early breast cancer treatment, but effects on survival are controversial. This multicentre, randomized pragmatic equivalence trial compares outcomes for post-menopausal early invasive breast cancer patients after locoregional treatment with ALNC and adjuvant therapies to outcomes after locoregional treatment without ALNC and adjuvant therapies., Methods: From 1995-2005, women aged ≥ 50 years with early breast cancer (tumor ≤ 10 mm) and clinically-negative axillary nodes were randomized to receive treatment with ALNC (Ax) or without (no-Ax). Adjuvant therapies were prescribed according to hormonal receptor status and individual histological results. The primary endpoint was overall survival (OS); secondary endpoints were event-free survival (EFS) and functional outcomes. The trial was terminated due to lack of equivalence and low accrual after first interim analyses., Trial Registration: NCT00210236., Results: Of 625 patients, 297 no-Ax and 310 Ax patients were maintained for final per-protocol analyses. OS and EFS at five years were not equivalent (Ax vs. no-Ax: 98% vs. 94% and 96% vs. 90% respectively). Recurrence was higher for no-Ax, particularly in the first five years after surgery. Axillary nodes were positive for 14% Ax patients but only 2% no-Ax patients experienced axillary node recurrence. Functional impairments were greater after ALNC., Conclusion: Our results fail to demonstrate equivalence of outcomes when ALNC is omitted from post-menopausal early breast cancer patient treatment. However the low locoregional recurrence rates warrant further examination over a longer duration, in particular to consider whether these would impact on survival., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
44. [Intraoperative molecular assessment of sentinel nodes in the breast cancer using the Gene Search BLN Assay technique: our experience about 126 patients].
- Author
-
Houpeau JL, Baranzelli MC, Giard S, Chauvet MP, Robin YM, Farre I, Andre C, Vilain MO, and Bonneterre J
- Subjects
- Breast Neoplasms pathology, Female, Humans, Predictive Value of Tests, Sensitivity and Specificity, Breast Neoplasms genetics, Breast Neoplasms surgery, Intraoperative Care methods, Reverse Transcriptase Polymerase Chain Reaction, Sentinel Lymph Node Biopsy
- Abstract
Introduction: Intraoperative molecular assay Gene Search BLN Assay (BLN) detects sentinel lymph node (SLN) metastasis in breast cancer. Our objective was to compare BLN to the definitive conventional histologic methods and to experiment the management of BLN in routine., Material and Methods: Each SLN was cut into alternate slabs. Half slabs were analysed with the intraoperative BLN molecular method, and the other slabs with the definitive histologic method., Results: Two hundred and thirty four SLN have been analysed (124 patients). Thirty-five SLN had metastasis for 29 patients (23.4%). BLN correctly identified 28 patients. Two cases of discordance between BLN and standard method were found, probably explained by a sample bias. The sensibility of BLN is 96.4%, the sensitivity is 99%, the predictive positive value is 96.4%, the predictive negative value is 99% and the concordance is 98.4%. The surgery time increases and there is a need to adapt the theatre organization accordingly., Conclusion: The Gene Search BLN Assay gives a great interest for the patient, the surgeon and the pathologist because it increases the quality of the intraoperative analysis by comparison with the intraoperative conventional histology., (Copyright © 2011 Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
45. [Sentinel node biopsy under local anesthesia for breast cancer: controversies].
- Author
-
Giard S
- Subjects
- Contraindications, Female, Humans, Patient Satisfaction, Anesthesia, Local, Breast Neoplasms pathology, Sentinel Lymph Node Biopsy methods
- Published
- 2011
- Full Text
- View/download PDF
46. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk.
- Author
-
Tunon-de-Lara C, Lemanski C, Cohen-Solal-Le-Nir C, de Lafontan B, Charra-Brunaud C, Gonzague-Casabianca L, Mignotte H, Fondrinier E, Giard S, Quetin P, Auvray H, and Cutuli B
- Subjects
- Adult, Age Factors, Breast Neoplasms diagnosis, Breast Neoplasms radiotherapy, Carcinoma in Situ diagnosis, Carcinoma in Situ radiotherapy, Carcinoma in Situ surgery, Carcinoma, Ductal, Breast diagnosis, Carcinoma, Ductal, Breast radiotherapy, Carcinoma, Ductal, Breast surgery, Disease-Free Survival, Female, Follow-Up Studies, France epidemiology, Humans, Kaplan-Meier Estimate, Mastectomy, Modified Radical, Mastectomy, Segmental, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local prevention & control, Patient Care Team, Predictive Value of Tests, Prognosis, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Breast Neoplasms epidemiology, Breast Neoplasms surgery, Carcinoma in Situ epidemiology, Carcinoma, Ductal, Breast epidemiology, Neoplasm Recurrence, Local epidemiology
- Abstract
Background: After breast conservative treatment (BCT), young age is a predictive factor for recurrence in patients with Ductal Carcinoma In Situ (DCIS) of the breast. The purpose of this study was to evaluate predictive factors for recurrence and outcomes in these younger women (under 40 years) treated for pure DCIS., Methods: From 1974 to 2003, 207 cases were collected in 12 French Cancer Centers. Median age was 36.3 years and median follow-up 160 months. Seventy four (35.8%) underwent mastectomy, 67 (32.4%) lumpectomy alone and 66 (31.9%) lumpectomy plus radiotherapy., Results: 37 recurrences occurred (17.8%): 14 (38%) were in situ and 23 (62%) invasive. After BCT, the overall rate of recurrence was 27% (33% in the lumpectomy plus radiotherapy group vs. 21% in the lumpectomy alone group). Comedocarcinoma subtype (p = 0.004), histological size more than 10 mm (p = 0.011), necrosis (p = 0.022) and positive margin status (p = 0.019) were statistically significant predictive factors for recurrence. The actuarial 15-year rates of local recurrence were 29%, 42% and 37% in the lumpectomy alone, lumpectomy and whole breast radiotherapy and lumpectomy + whole breast radiotherapy with additional boost groups respectively. After recurrence, the 10-year overall survival rate was 67.2%., Conclusion: High recurrence rates (mainly invasive) after BCT in young women with DCIS are confirmed. BCT in this subgroup of patients is possible if clear and large margins are obtained, tumor size is under 11 mm and necrosis- and/or comedocarcinoma-free., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
47. Is there a reliable method to assess the complete pathologic response on the tumor after neo-adjuvant chemotherapy in inflammatory breast cancer toward recommendations for the pathologic process? Experience in 56 patients treated in a single institution.
- Author
-
Mailliez A, Baranzelli MC, Giard S, Ceugnart L, Vanlemmens L, Belkacemi Y, Robin YM, and Bonneterre J
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Humans, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Antineoplastic Agents therapeutic use, Inflammatory Breast Neoplasms drug therapy, Inflammatory Breast Neoplasms pathology, Neoplasm Recurrence, Local
- Abstract
The aim of this study was to compare the complete pathologic response (CPR) rate in 56 nonmetastatic inflammatory breast cancer patients according to the classification used and to look for a correlation between the CPR and overall survival. Initial biopsies and mastectomy specimens were reviewed by the same pathologist. The clinical response rate was 75%. A CPR was observed in 11 cases according to Sataloff, three according to Chevallier and five according to the NSABP. There was no correlation between the clinical and pathologic responses and none of them was predictive of relapse free survival or overall survival. We propose a standardization of the pathologic process of the mastectomy specimens so that a CPR has a clear definition across the institutions, with a good reproducibility whatever the classification used., (© 2010 Wiley Periodicals, Inc.)
- Published
- 2010
- Full Text
- View/download PDF
48. Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502).
- Author
-
Giard S, Chauvet MP, Penel N, Mignotte H, Martel P, Tunon de Lara C, Gimbergues P, Dessogne P, Classe JM, Fondrinier E, and Marmousez T
- Subjects
- Adult, Aged, False Negative Reactions, Feasibility Studies, Female, Humans, Middle Aged, Prospective Studies, Risk Factors, Breast Neoplasms pathology, Sentinel Lymph Node Biopsy
- Abstract
Background: To prospectively determine the feasibility of sentinel lymph node biopsy (SLNB) in preoperatively diagnosed multiple unilateral synchronous invasive breast cancers., Patients and Methods: The Interest of Axillary Sentinel Lymph Node Biopsy in Multiple Invasive Breast Cancer (IGASSU) study was a prospective multi-institutional study with initial breast surgery, SLNB, and systematic axillary lymph node dissection (ALND). Patients eligible for the IGASSU study had an operable invasive multiple synchronous tumor (MST), defined as two or more physically separate invasive tumors in the same or different quadrant., Results: From 1 March 2006 to 31 August 2007, 216 patients were prospectively included from 16 institutions. Of these patients, 211 were assessable. The SLNB-identified rate was 93.4% (197 of 211). The false-negative rate (FNR) was 13.6% (14 of 103) [95% confidence interval (CI) 7% to 20%], and the accuracy was 92.9% (183 of 197) (95% CI 89% to 96%). In a univariate analysis, tumor location (only external location versus other location) was the only clinicopathological factor influencing the FNR [22% (11%-33%) versus 7% (4%-10%)], even then median aggregate histological tumor size was smaller in external tumors [17 mm (range 12-80 mm) versus 34 mm (range 8-90 mm), P = 0.016]., Conclusion: With a FNR of 13.6%, we do not recommend SLNB as a routine procedure for MST, even for small tumor.
- Published
- 2010
- Full Text
- View/download PDF
49. [Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases].
- Author
-
Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S, Lancrenon S, Meunier A, Pioud-Martigny R, Campana F, Marsiglia H, Mery E, Penault-Llorca F, Fondrinier E, and de Lara CT
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal administration & dosage, Axilla, Cross-Sectional Studies, Female, France, Humans, Lymph Node Excision statistics & numerical data, Mastectomy statistics & numerical data, Middle Aged, Prospective Studies, Radiotherapy Dosage, Sentinel Lymph Node Biopsy statistics & numerical data, Breast Neoplasms pathology, Breast Neoplasms therapy, Carcinoma in Situ pathology, Carcinoma in Situ therapy, Carcinoma, Ductal, Breast pathology, Carcinoma, Ductal, Breast therapy
- Abstract
From March 2003 to April 2004, were prospectively collected in France 1,289 ductal carcinoma in situ (DCIS) with data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30-84). DCIS was diagnosed by mammography in 87.6% of patients. Mastectomy (M), conservative surgery alone (CS) and conservative surgery with radiotherapy (CS + RT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients, respectively. Hormone therapy was administered to 13.4% of the patients. Nuclear grade was low in 21% of patients, intermediate in 38.5% and high in 40.5%. Excision was considered complete in 92% (CS) and 88.3% (CS + RT) of patients. Treatment modalities varied widely according to region: mastectomy rate, 20-37%; adjuvant RT, 84-96%; hormone treatment, 6-34%. Our survey on current DCIS management in France has highlighted correlations between pathological features (tumour size, margin, grade) and treatment options, with several similar variations to those observed in recent UK and US studies.
- Published
- 2010
- Full Text
- View/download PDF
50. [Intraoperative determination of axillary node metastasis by RT-PCR].
- Author
-
Baranzelli MC, Penault-Llorca F, Revillon F, Portefaix G, Mishellany F, Chauvet MP, Giard S, Dauplat MM, Gimbergues P, Robin YM, Dauplat J, and Bonneterre J
- Subjects
- Adult, Axilla, Breast Neoplasms surgery, Female, Humans, Immunohistochemistry methods, Intraoperative Period, Sensitivity and Specificity, Breast Neoplasms pathology, Lymphatic Metastasis diagnosis, Reverse Transcriptase Polymerase Chain Reaction methods, Sentinel Lymph Node Biopsy methods
- Abstract
Unlabelled: The intraoperative determination of axillary node micrometastasis according to the Rapid GeneSearch Breast Lymph Node (BLN) is based on RT-PCR (mRNA of mammaglobine and CK19) detects metastases > 0.2 mm., Patients and Methods: Eighty-three pts between November 2007 and June 2008 were included (33 from Centre Jean-Perrin and 50 from Centre Oscar-Lambret). Lymph nodes were cut in 2 mm slices, and 1 out of 2 was examined with BLN; the others were examined by imprints then histological exam with immunohistochemistry., Results: Forteen pts had micro- or macrometastasis. Seven were positive with intraoperative imprints including six macrometastasis and one micrometastasis; seven were positive with BLN and seven at histological exam with two cases of discordance. Sensitivity was 92%, specificity 98%. Positive predictive value 92%, and negative predictive value 98%. The median time for intraoperative determination was 40 minutes for 2 SLN., Discussion: Half each lymph node is study by each method. This explains the discordances observed. Limit of BLN is the absence of CTI detection; however there is no consensus about the necessity of axillary clearance in such a case., Conclusion: In this series BLN reduces axillary clearance and improves comfort patients.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.